Replimune is pioneering a new class of tumor directed oncolytic immunotherapies (TDOI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company’s approach is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to not only directly kill tumors and generate systemic anti-cancer immune responses, but to also create a practical, in situ approach to achieving personalized systemic anti-cancer vaccination. The approach is expected to be highly synergistic with immune checkpoint blockade and other methods of treatment across a broad range of cancers. With deep experience across drug development and commercialization, the Replimune team is now focused on delivering therapies to patients that are intended to be significant improvements compared to what was previously possible, and which will broaden the use of OI well beyond immune responsive cancers to the full range of solid tumor types. Since September 2015, Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma – and will be the basis for establishing a broad skin cancer franchise. Two further product candidates, RP2 and RP3, are currently in Phase 1/2 clinical development. Replimune has completed buildout of its 63,000-square-foot state-of-the-art GMP manufacturing facility which will support later-stage development and full commercialization of all of its products.